TICKERNERD
Menu
QUREQUREHealthcare · Biotechnology

QURE Stock Forecast: UniQure NV Price Predictions for 2026-2027

Last close, 14 Aug 2026
$49
+3.31% on the day

The 12 Wall Street analysts covering UniQure NV hold a median 12-month price target of $69 — +42.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 54 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$3.4B
Ticker Nerd rank
54 / 100
Median analyst target
$69
Analysts covering
12
Total return, dividends reinvested
1W
+4.7%
1M
+17.1%
YTD
+103.2%
1Y
+208.1%
From 52W high
−31.1%
From 52W low
+438.4%
$9
$71
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

QURE stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores UniQure NV on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
54 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
88
Momentum
81
Value
67
Accruals
65
Growth
54
Revisions
49
Size
30
Issuance
16
Volatility
14

Quality (88): The business earns solid, repeatable profits on what it owns.

Volatility (14): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

QURE stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on QURE, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0$20$40$60$80$100Oct 25Jan 26Apr 26Jul 26QUREHigh $97Median $69Low $47

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says12 analysts
11 Buy1 Hold0 Sell
Low $47Median $69High $97

The green dot is the last close — the median target sits +42.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
30 July 2026BarclaysMaintainsOverweight$65 → $60
30 July 2026Wells FargoMaintainsOverweight$60 → $75
30 July 2026Wolfe ResearchUpgradeOutperform$65
29 June 2026HC Wainwright & Co.MaintainsBuy$50 → $80
29 June 2026HC Wainwright & Co.MaintainsBuy—
25 June 2026MizuhoMaintainsOutperform$35 → $68
25 June 2026MizuhoMaintainsOutperform—
18 June 2026BarclaysUpgradeOverweight—
18 June 2026Goldman SachsMaintainsNeutral—
18 June 2026Leerink PartnersMaintainsOutperform—
18 June 2026RBC CapitalMaintainsOutperform—
6 May 2026HC Wainwright & Co.MaintainsBuy—
30 Apr 2026Chardan CapitalMaintainsBuy—
20 Apr 2026Goldman SachsMaintainsNeutral—
23 Mar 2026BarclaysMaintainsEqual-Weight—
11 Mar 2026MizuhoUpgradeOutperform—
10 Mar 2026HC Wainwright & Co.ReiteratesBuy—
9 Mar 2026Chardan CapitalMaintainsBuy—
9 Mar 2026RBC CapitalUpgradeOutperform—
9 Mar 2026Wells FargoUpgradeOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. QURE appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

QURE analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

UniQure NV (QURE) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−14.1×

Cheaper than 94% of US stocks

Price / sales
180.6×

Cheaper than 3% of US stocks

Price / book
10.4×

Cheaper than 10% of US stocks

EV / EBITDA
−17.0×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
11.0%

Higher than 55% of US stocks

Earnings growth (YoY)
11.0%

Higher than 49% of US stocks

Gross margin
94.0%

Higher than 98% of US stocks

Operating margin
−872.2%

Higher than 6% of US stocks

Net margin
89.5%

Higher than 99% of US stocks

Returns & dividend
Return on equity
−157.6%

Higher than 8% of US stocks

Return on assets
−15.7%

Higher than 22% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

QURE vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
QUREUniQure NV$3.4B
54
MBXMBX Biosciences, Inc.$3.3B
35
ARQTArcutis Biotherapeutics, Inc.$3.2B
89
CLDXCelldex Therapeutics, Inc.$3.2B
31
IDYAIDEAYA Biosciences, Inc.$3.4B
80
ALMSAlumis, Inc.$3.2B
51
ABCLAbCellera Biologics, Inc.$3.4B
71

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own UniQure NV — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest QURE news & analysis

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Seeking Alpha · 17 Aug 2026positive

The article reports that biotech stocks, particularly small-cap names, are seeing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.

Why it matters — As a small-cap biotech, QURE operates in the broader sector environment described, so improving FDA stability, renewed M&A/IPO activity, and restored capital flows could be relevant to its investor landscape.

QURE Q2 Earnings Miss Estimates on Higher Costs, Revenues Rise Y/Y

Zacks Investment Research · 30 July 2026neutral

UniQure reported a wider-than-expected loss for Q2 2026, with revenues falling short of estimates despite rising year over year, while highlighting regulatory progress for AMT-130 and a cash runway extending into 2030.

Why it matters — A QURE watcher would care because the earnings miss is balanced by progress on its key gene-therapy candidate AMT-130 and enough cash to fund operations through the end of the decade.

uniQure N.V. (QURE) Q2 2026 Earnings Call Transcript

Seeking Alpha · 29 July 2026neutral

Seeking Alpha published the transcript of uniQure N.V.'s Q2 2026 earnings call.

Why it matters — The earnings call transcript provides a detailed record of management's discussion on Q2 2026 financial results and business developments, which is essential for investors tracking the company's performance.

uniQure Q2 Earnings Call Highlights

MarketBeat · 29 July 2026positive

UniQure announced it has aligned with the FDA on a potential accelerated-approval pathway for AMT-130, its gene therapy for Huntington's disease, and is on track to submit a biologics license application in Q3 2026.

Why it matters — This regulatory alignment brings AMT-130 closer to potential market approval, which is a pivotal milestone for UniQure's lead pipeline candidate.

uniQure (QURE) Reports Q2 Loss, Misses Revenue Estimates

Zacks Investment Research · 29 July 2026negative

UniQure reported a Q2 loss of $1.22 per share, wider than both the Zacks Consensus Estimate of a $0.81 loss and the $0.69 loss reported in the same quarter last year.

Why it matters — The quarterly results missed analyst expectations and showed a larger year-over-year loss, which investors tracking QURE's financial performance would note.

FAQ

Frequently asked questions about QURE stock

What is the QURE stock price forecast for 2026-2027?

The 12 Wall Street analysts covering UniQure NV have a median 12-month price target of $69, with estimates ranging from $47 to $97. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is QURE stock a buy right now?

Of the 12 analysts covering UniQure NV, 11 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks UniQure NV 54 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank QURE?

As at 15 Aug 2026, UniQure NV ranks 54 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (88 of 100).

Will QURE stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +42.2% from the last close, and Ticker Nerd's factor model ranks UniQure NV 54 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the QURE stock forecast for 2030?

No analyst covering UniQure NV publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for QURE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $47 to $97 over the next 12 months.

How has QURE stock performed over the past year?

UniQure NV returned +208.1% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does UniQure NV do?

uniQure N.V. is a biotechnology company specializing in gene therapy, focused on developing single-treatment interventions for rare and other severe diseases.

What is the latest news on QURE?

The most recent item we track (Seeking Alpha, 17 Aug 2026): "Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes". The article reports that biotech stocks, particularly small-cap names, are seeing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.

Company

About UniQure NV.

uniQure N.V. is a biotechnology company specializing in gene therapy, focused on developing single-treatment interventions for rare and other severe diseases. Headquartered in Amsterdam, the Netherlands, and founded in 1998, uniQure leverages an adeno-associated virus (AAV) platform to deliver genetic material designed to restore or modulate protein expression in targeted tissues. The company’s commercial activities and partnerships center on AAV-based therapies for liver-directed and central nervous system disorders, including programs in Huntington’s disease, refractory temporal lobe epilepsy, ALS, Fabry disease, and hemophilia. uniQure’s technology platform and internal manufacturing capabilities support research, early clinical development, and late-stage programs, positioning it as a key player in advanced therapies for neurodegenerative and other life-threatening conditions. By focusing on diseases with high unmet medical need and using a modular gene therapy platform, uniQure plays a significant role in the healthcare market segment dedicated to innovative, potentially transformative genetic medicines.

CEO Mr. Matthew Craig Kapusta CPA · 221 employees · Netherlands · https://www.uniqure.com